Panelists discuss how the JADE EXTEND study (Shi 2022) found that most patients who achieved EASI-75 with dupilumab also responded to abrocitinib. Even some dupilumab nonresponders achieved EASI-75. Adverse events (AEs) included nausea, acne, and headache.
Panelists discuss how the JADE COMPARE study (Bieber 2021) found similar EASI-75 response rates at 16 weeks for abrocitinib (71.0% at 200 mg, 60.3% at 100 mg) and dupilumab (65.5%). Abrocitinib had more nausea/acne; dupilumab had more conjunctivitis. Adverse effect (AE) withdrawal rates were low.
Panelists discuss how the Measure Up 1 and 2 studies (Simpson 2022) showed that at 52 weeks, 82.0% to 84.9% of upadacitinib patients achieved EASI-75. Common adverse effects (AEs) included acne, cough, and headache, with 4.5% to 7.2% withdrawal rates.
Panelists discuss how Janus kinase (JAK) inhibitors such as upadacitinib, abrocitinib, and baricitinib offer rapid, oral treatment for moderate to severe atopic dermatitis, differing from injectable biologics in administration, broader immunosuppression, and risk of adverse events like thromboembolism. They provide effective symptom control but require safety monitoring.
Latanya Benjamin, MD, and Lindsay Ackerman, MD, joins The Medical Sisterhood in a live recording at AAD 2025 to discuss advocacy, mentorship, and empowerment.
Panelists discuss how the 2-year ECZTEND study found tralokinumab effective for atopic dermatitis, with 82.5% achieving EASI-75 and 59.8%, EASI-90. Common adverse effects (AEs) included upper respiratory tract infections, dermatitis, headache, and conjunctivitis. The treatment-emergent adverse event (TEAE) withdrawal rate was 1.6%.
Panelists discuss how The LIBERTY AD OLE study (Beck 2024) showed sustained efficacy of treatment in atopic dermatitis, with 96.9% achieving EASI-50; 88.9%, EASI-75; and 80.7%, EASI-90 over 260 weeks. Common adverse events (AEs) included nasopharyngitis, atopic dermatitis (AD) worsening, upper respiratory tract infections, herpes infections, and conjunctivitis. Treatment-emergent adverse event (TEAE)–related withdrawal was 3.8%.
Panelists discuss how common adverse effects impact treatment decisions, requiring adjustments. Experienced adverse reactions are managed with tailored interventions, monitoring, and patient education to ensure optimal care.
Panelists discuss how primary care awareness of biologics and Janus kinase (JAK) inhibitors for atopic dermatitis (AD) remain limited, with outreach efforts by dermatology groups and industry partners showing mixed success in education. While patients on biologics generally report significant symptom improvement, measured through validated tools like EASI, SCORAD, and patient-reported outcome measures, ongoing efforts are needed to bridge the knowledge gap in primary care settings.
Panelists discuss how the emergence of targeted biologics has revolutionized atopic dermatitis treatment by offering effective alternatives to traditional therapies. These agents, including IL-4/IL-13 inhibitors like dupilumab and others targeting specific inflammatory pathways, have provided new options for moderate to severe cases resistant to conventional treatments.
Panelists discuss how upcoming topical therapeutics for atopic dermatitis include corticosteroid-sparing treatments like topical calcineurin inhibitors (eg, tacrolimus, pimecrolimus), Janus kinase (JAK) inhibitors (eg, ruxolitinib), and phosphodiesterase-4 inhibitors (eg, crisaborole) for effective symptom management.
Panelists discuss how primary care physicians often serve as the first point of contact for patients with atopic dermatitis symptoms. Dermatologist referral is typically considered when patients show severe or persistent symptoms despite initial treatment, have unclear diagnosis, require specialized therapies, or experience significant impact on quality of life.
Panelists discuss how atopic dermatitis severity classification relies on multiple assessment tools including EASI, SCORAD, POEM, and BSA measurements. Special attention is given to sensitive areas (hands, feet, genitals) as they significantly impact quality of life. Disease extent, intensity of symptoms, and functional impairment guide categorization into mild, moderate, or severe cases.
In this episode, James Q. Del Rosso, DO, joins The Medical Sisterhood for a conversation about empowerment and the benefits of female role models.
Panelists discuss how they assess atopic dermatitis across all age groups by evaluating clinical history, symptom severity, and physical examination. They consider factors like age-specific presentations, comorbid conditions, and response to treatment for individualized management.
Panelists discuss how adult atopic dermatitis diagnosis relies on clinical presentation of chronic, pruritic, and eczematous lesions with characteristic distribution patterns. Unlike children, adults show more lichenified plaques and predominant hand/foot involvement. Key diagnostic criteria include personal/family history of atopy and chronic/relapsing course. No definitive test exists.
Shadi Kourosh, MD, MPH, joins The Medical Sisterhood to discuss advocacy, mentorship, and the empowerment of women in medicine.
Susan Taylor, MD, and Linda Stein Gold, MD, join The Medical Sisterhood for an intimate conversation on the importance of role models and mentors.
Alexandra Golant, MD, joins the program for a deep dive into her experience with motherhood, striking an optimal balance between her career and her personal life, and more!
In this episode, Tina Bhutani, MD, MAS, joins The Medical Sisterhood for a discussion about confronting imposter syndrome as a woman in medicine.
The Medical Sisterhood, hosted by Mona Shahriari, MD, is the latest multimedia program from HCPLive Dermatology!
Experts conclude the series discussing how to approach switching psoriasis treatments.
Experts discuss package warnings associated with bimekizumab and how they inform patients of them.
Experts discuss bimekizumab for the treatment of psoriasis highlighting is efficacy over other treatments.
Experts discuss the warnings regarding IL-17 blockers and inflammatory bowel disease.
Experts emphasize the importance of collaboration with infectious disease specialists for patients with tuberculosis, while highlighting the low reactivation rates in newer agents.
Experts highlight how a history of cancer may impact psoriasis treatment decisions while touching on the safety profiles of newer IL agents.
Experts discuss common comorbidities for patients with plaque psoriasis and how they can impact treatment decisions.
Experts discuss the landscape of IL therapies for the treatment of psoriasis, highlighting their improved safety and efficacy over prior agents.
Experts discuss the use of TNF blockers in treating plaque psoriasis and their limited but important uses today.
